Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis

  • By

  • Rong Chen

  • Zhenyu Huo

  • Xuelin Yang

  • Xiaohu Cui

  • Xin Liu

  • Fang Wang

  • February 19, 2026

  • 0 min

Share

  • 1

    Immunocompromised individuals have a distinct cancer profile, with high-risk cancers linked to viral infections and immune suppression.

  • 2

    Infection-related cancers accounted for 13% of global cancer cases by 2018, highlighting significant health risks in immunocompromised populations.

  • 3

    Tumor mutational burden (TMB) serves as a potential biomarker for immunogenicity and may predict responses to immune checkpoint inhibitors.

  • 4

    This study conducted a systematic review to analyze infection-associated cancer risks in solid organ transplant, hematopoietic stem cell transplant recipients, and PLHIV.

  • 5

    Findings suggest that high-TMB cancers may be more prevalent in immunocompromised patients, correlating cancer risk with TMB levels.

Original Source(s)

Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis

  • by Rong Chen, Zhenyu Huo, Xuelin Yang, Xiaohu Cui, Xin Liu, Fang Wang

  • February 19, 2026

Related Content

Redox-metabolic circuits as a central regulator of T cell-based immunotherapy

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

Dana-Farber Research News 02.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 16 - 31.

  • February 15, 2026

  • 21 min